Inventiva S.A. (IVA), a biopharmaceutical company specializing in oral small molecule therapies for non-alcoholic steatohepatitis (NASH) and other diseases, saw its shares soar 6.70% in pre-market trading on Thursday. The significant uptick comes as investors eagerly await the company's second-quarter earnings report, scheduled for release after the market closes.

The pre-market rally suggests a wave of optimism among investors regarding Inventiva's upcoming financial disclosure. While analysts surveyed by FactSet Research Systems Inc. project a loss of $0.63 per share for the quarter, the strong stock movement indicates that market participants may be anticipating better-than-expected results or positive updates on the company's drug pipeline.

Investors will be paying close attention to any news regarding Inventiva's lead drug candidate, lanifibranor, which is currently undergoing Phase III clinical trials for NASH treatment. The earnings report is expected to provide crucial insights into the progress of ongoing studies and potential milestones, which could significantly impact the stock's performance in the near future. As the biopharmaceutical sector continues to attract interest, Inventiva's financial results and pipeline updates will be closely scrutinized for signs of progress in addressing unmet medical needs.